Technicians work in the ISO-certified cleanroom laboratory at Cincinnati Children’s where gene-correction therapies are tested and produced for clinical trials like the one for sickle cell anemia presented by Punam Malik MD, at this year’s annual meeting of the American Society of Hematology in San Diego.
Treatment Uses Reduced-Intensity Preconditioning to Enhance Its Global Transportability
After over a decade of preclinical research and development, a new gene therapy treatment for sickle cell anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.
Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology’s (ASH) annual meeting in San Diego by principal investigator Punam Malik, MD. She is a physician-scientist at the Cincinnati Children’s Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center. Malik called the data promising.
“One year after treatment of our first patient, and six months after treatment of our second patient, both have seen a remarkable improvement in the quality of life due to remarkable reduction in disease symptoms. This includes near elimination of chronic pain and sickling events and improved anemia,” Malik said. “Although it’s still early post-treatment, these preliminary results are quite promising. If sustained this therapy will provide a transportable, safe and feasible gene therapy for all SCA patients.”
SCA is a painful, inherited disease where blood cells become sickle-shaped and stuck in the vascular system. It can damage vital organs and cause death.
How the Therapy Works
The gene therapy developed by Cincinnati Children’s uses a modified gamma globin lentivirus vector to transfer a healthy fetal hemoglobin gene into a patient’s blood stem cells (hematopoietic stem cells, HSC). The lentivirus is modified so it does not cause illness.
The therapy comes from the observation that some adults never stop producing fetal hemoglobin (HbF). This prevents red blood cell sickling when sufficient quantities of HbF are present in the body. Normally, the fetal hemoglobin gene switches off shortly after birth. The new gene therapy approach designed by Malik and team places a fetal hemoglobin gene in the bone marrow cells that cannot switch off.
Cells are collected earlier from the SCA patient and genetically reprogrammed in a clean lab facility with the modified lentivirus vector. Then the patient’s bone marrow is preconditioned with one low-dose of chemotherapy, after which the gene-corrected cells are infused back into the patient. Patients recover their blood counts within a week to 10 days and recover from the chemotherapy effects by two weeks, Malik said.
A key feature of the treatment regimen is the reduced-intensity preconditioning for patients receiving the therapy for SCA. The method is less toxic and expensive than myeloablative preconditioning normally used in bone marrow transplants, according to the researchers.
Myeloablative conditioning uses high-intensity chemotherapy to prepare a transplant patient’s bone marrow for healthy gene-corrected blood stem cells (HSCs). This typically results in low blood counts and other side effects. These can include severe infections and long stays in transplant units for one or two months.
This means transplants using myeloablative conditioning have to be performed at large and sophisticated medical centers in developed parts of the world. Malik said this limits access to people in underdeveloped regions where SCA is more common, like Africa, India, the Caribbean and South America.
Reaching High-Need Regions
One goal for Malik and her colleagues is that their therapy’s reduced intensity conditioning will allow it to be offered at hospitals in places like Central Africa and other underdeveloped regions of the world.
SCA affects more than 90,000 people in the United States, and millions of people worldwide have the disease, according to the researchers.
Malik said additional data from the study will tell investigators of the consistent and long-term clinical benefit of this therapy to patients with severe SCA. The trial is scheduled to treat up to 10 patients with SCA. Preclinical studies by the research team suggested the treatment allows the body to produce normal red blood cells instead of the sickle-shaped cells that define the inherited disorder.
Improved Quality of Life
Both adult patients included in the ASH presentation are 35 and 25 years old who, respectively, had gene transfer therapy 15 and 12 months ago. In the year and a half prior to receiving gene-correction therapy, both patients had more than a dozen acute sickle events per year, according to Malik. These included acute chest and pain crises, chronic pain, and required the ongoing use of oral or injectable opioids on a regular basis.
Investigators report that one year following therapy, the first patient no longer requires daily oral opioids for chronic pain and has had one acute sickle cell event. The second patient no longer uses oral opioids and has no vaso-occlusive events, where blood cells become stuck in the vascular system.
Learn more: Early Clinical Trial Data Show Gene Therapy Reversing Sickle Cell Anemia
The Latest on: Sickle cell anemia
via Google News
The Latest on: Sickle cell anemia
- Surviving five decades of living with sickle cell anemia – The story of 49-year-old Ama Nyarko Attafuah Quainooon May 14, 2022 at 2:20 pm
Imagine being in excruciating pain, constantly worn out and exhausted. That’s what it feels like living with sickle cell anaemia, an inherited blood disease.
- Surviving nearly five decades of living with sickle cell anemia – The story of 49-year-old Ama Nyarko Attafuah Quainooon May 14, 2022 at 2:20 am
Imagine being in excruciating pain, constantly worn out and exhausted. That’s what it feels like living with sickle cell anaemia, an inherited blood disease. Ama Nyarko Attafuah Quainoo, 49, has had ...
- Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemiaon May 12, 2022 at 1:32 pm
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational ...
- Adolescent, Young Adult Males With Sickle Cell Disease Lack Knowledge of Fertility Implications, Study Showson May 12, 2022 at 8:28 am
Improved management of sickle cell disease has vastly improved life expectancy and reduced morbidity for affected patients, but the disease itself and its treatments carry fertility risks that many ...
- GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congresson May 12, 2022 at 7:02 am
New real-world evidence dataon Oxbryta®(voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted. SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE ...
- Blazers star Damian Lillard reaches out to fan in Arkansas battling sickle cell: ‘That meant everything’on May 10, 2022 at 6:29 am
Lillard discovered Kayden because of a video from Tommy Norman, an officer of the North Little Rock Police Department. When Norman heard of Kayden’s battle with sickle cell, he ...
- Community holds sickle cell anemia drive to support 6-year-old boyon May 7, 2022 at 5:50 pm
On Saturday, May 7, the ArkLaTex community came together to support six-year-old “Braxton the Brave” at a sickle cell anemia drive. The drive was put together by Barbara Norton and community ...
- Braxton The Brave fights sickle cell anemiaon May 7, 2022 at 3:22 pm
SHREVEPORT, La. - A sickle cell drive was held in Shreveport Saturday to help a brave little boy fight sickle cell anemia. The drive was held in honor of six-year-old, Brandon Brooks The Brave at Bill ...
- Sickle cell and authenticityon May 6, 2022 at 9:47 pm
What is sickle cell disease? Sickle cell anaemia is a disease where the normal red blood cells are round but for people living with sickle cell, theirs is the shape of a sickle and hence the name.
via Bing News